PALOMA-4 is a randomized, double-blind phase III study of palbociclib plus letrozole versus placebo plus letrozole for the treatment of previously untreated Asian postmenopausal women with HR+/HER2− advanced BC [30]. This evidence concerns the gene HR and breast cancer.